SCPHARMACEUTICALS INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-04-19: Study NCT06167707; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2023-06-02: Study NCT05528588; Company role Collaborator; Phase Phase 2; Status Completed.
- 2021-05-03: Study NCT04593823; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2020-11-12: Study NCT03458325; Company role Lead sponsor; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-04-19 | NCT06167707 Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers | Lead sponsor | Phase 1 | Completed Results posted | Heart Failure; Fluid Overload | 21 | 2024-06-14 |
| 2023-06-02 | NCT05528588 Furoscix in Heart Failure Patients With Diuretic Resistance | Collaborator Lead: University of Texas Southwestern Medical Center | Phase 2 | Completed Results posted | Heart Failure | 70 | 2024-07-01 |
| 2021-05-03 | NCT04593823 Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study | Lead sponsor | Phase 2 | Completed Results posted | Heart Failure | 63 | 2022-04-18 |
| 2020-11-12 | NCT03458325 Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure | Lead sponsor | Phase 3 | Completed Results posted | Heart Failure | 27 | 2021-06-24 |
| 2019-12-02 | NCT04161482 An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability | Lead sponsor | Phase 1 | Completed | Healthy | 39 | 2020-06-26 |
| 2016-07 | NCT02804282 Product Design Clinical Performance Study of sc2Wear Furosemide Combination Product | Lead sponsor | Phase 3 | Completed | Heart Failure | 74 | 2016-11 |
| 2016-07 | NCT02804035 Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product | Lead sponsor | Phase 2 | Completed | Heart Failure | 27 | 2016-08 |
| 2016-05 | NCT02721511 A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen | Collaborator Lead: Todd M Koelling, MD | Phase 1, Phase 2 | Withdrawn | Acute Decompensated Heart Failure | 0 | 2017-03-07 |
| 2016-02 | NCT02579057 Sub-Q Versus IV Furosemide in Acute Heart Failure | Collaborator Lead: Johns Hopkins University | Phase 2, Phase 3 | Completed Results posted | Congestive Heart Failure | 40 | 2017-07 |
| 2015-10 | NCT02561442 Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration | Lead sponsor | Phase 2, Phase 3 | Completed | Pharmacokinetics in Healthy Adults | 18 | 2015-12 |
| 2015-04 | NCT02329834 Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | Heart Failure | 23 | 2015-10 |
| 2014-12 | NCT02350725 Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration | Lead sponsor | Phase 1, Phase 2 | Completed | Heart Failure | 10 | 2015-06 |